Quercetin inhibits p21‐RAS expression in human colon cancer cell lines and in primary colorectal tumors

Immunocytochemical studies have revealed that 10 μM quercetin reduced the steady state levels of p21‐ras proteins in both colon cancer cell lines and primary colorectal tumors. These findings were confirmed by Western blot and flow cytometric analysis showing that the inhibition of p21‐ras expressio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2000-02, Vol.85 (3), p.438-445
Hauptverfasser: Ranelletti, Franco O., Maggiano, Nicola, Serra, Fabio G., Ricci, Riccardo, Larocca, Luigi M., Lanza, Paola, Scambia, Giovanni, Fattorossi, Andrea, Capelli, Arnaldo, Piantelli, Mauro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Immunocytochemical studies have revealed that 10 μM quercetin reduced the steady state levels of p21‐ras proteins in both colon cancer cell lines and primary colorectal tumors. These findings were confirmed by Western blot and flow cytometric analysis showing that the inhibition of p21‐ras expression by quercetin was time‐ and concentration‐dependent. Twenty‐four‐hour treatment with 10 μM quercetin reduced p21‐ras levels to about 50% of control values. Quercetin was similarly effective in inhibiting the expression of K‐, H‐, and N‐ras proteins. Moreover, the effect of quercetin on ras oncogene expression was not dependent on the cell cycle position of colon cancer cells and appeared to be specific and not merely a consequence of overall inhibition of protein synthesis. Northern blot analysis revealed that quercetin produced in colon cancer cells an early (30 min) reduction of the steady state levels of K‐, H‐, and N‐ras mRNAs. This reduction was also present after 6 hr of flavonoid treatment. These effects of quercetin suggest a possible chemopreventive role for this compound in colorectal carcinogenesis. Int. J. Cancer 85:438–445, 2000. ©2000 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F